Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy

Arthritis Care and Research

Volumn 59, Issue 6, 2008, Pages 800-806

  Chen, Der Yuan ^a,b   Shen, Gwan Han ^b   Hsieh, Tsu Yi ^a,b,c   Hsieh, Chia Wei ^a,b   Lan, Joung Liang ^a,b,d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c DA YEH UNIVERSITY   (Taiwan)

^d TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CULTURE FILTRATE PROTEIN 10; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; ISONIAZID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; BIOLOGICAL THERAPY; BLOOD CULTURE; CLINICAL ARTICLE; CLONAL ANERGY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOASSAY; INFECTION PREVENTION; MALE; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOUS ARTHRITIS; TUBERCULOUS LYMPHADENITIS; TUBERCULOUS PLEURISY;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; INTERFERON TYPE II; MALE; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDIES; TUBERCULIN TEST; TUBERCULOSIS;

EID: 45349085489     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23705     Document Type: Article

References (55)

1. Hsueh PR, Liu YC, So J, Liu CY, Yang PC, Luh KT. Mycobacterium tuberculosis in Taiwan. J Infect 2006;52:77-85.
2. Carmona L, Hernandez-Garcia C, Vadillo C, Pato E, Balsa A, Gonzalez-Alvaro I, et al, and the EMECAR Study Group. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003;30:1436-9.
3. Bouza E, Moya JG, Munoz P. Infections in systemic lupus erythematosus and rheumatoid arthritis. Infect Dis Clin North Am 2001;15:335-61.
4. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001;345:1098-104.
5. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50:372-9.
6. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, on behalf of the BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7.
7. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148-55.
8. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48:35-45.
9. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:889-94.
10. Furst DE, Cush J, Kaufmann S, Siegel J, Kurth R. Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann Rheum Dis 2002;61Suppl 2:ii62-3.
11. Mariette X, Salmon D, and the Group RATIO. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 2003;62:791.
12. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM, et al, on behalf of the BIOBA-DASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766-72.
13. Pratt A, Nicholl K, Kay L. Use of the QuantiFERON TB Gold test as a part of a screening programme in patients with RA under consideration for treatment with anti-TNF-α agents: the Newcastle (UK) experience [letter]. Rheumatology (Oxford) 2007;46:1035-6.
14. Snider DE Jr. The tuberculin skin test. Am Rev Respir Dis 1982;125:108-18.
15. Porsa E, Cheng L, Seale MM, Delclos GL, Ma X, Reich R, et al. Comparison of a new ESAT-6/CFP-10 peptide-based γ interferon assay and a tuberculin skin test for tuberculosis screening in a moderate-risk population. Clin Vaccine Immunol 2006;13:53-8.
16. Brock I, Weldingh K, Lillebaek T, Follmann F, Andersen P. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 2004;170:65-9.
17. Bowerman RJ. Tuberculin skin testing in BCG-vaccinated populations of adults and children at high risk for tuberculosis in Taiwan. Int J Tuberc Lung Dis 2004;8:1128-33.
18. Ding LW, Lai CC, Lee LN, Hsueh PR. Disease caused by non-tuberculous mycobacteria in a university hospital in Taiwan, 1997-2003. Epidemiol Infect 2006;134:1060-7.
19. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A, the Division of Tuberculosis Elimination, the National Center for HIV, STD, and TB Prevention, and the Centers for Disease Control and Prevention. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States [published erratum appears in MMWR Morb Mortal Wkly Rep 2005;54:1288]. MMWR Recomm Rep 2005;54:49-55.
20. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet 2000;356:1099-104.
21. Ewer K, Deeks J, Alvarez L, Bryant G, Waller S, Andersen P, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 2003;361:1168-73.
22. Jensen PA, Lambert LA, Iademarco MF, Ridzon R, and the Centers for Disease Control and Prevention (CDC). Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep 2005;54:1-141.
23. Sellam J, Hamdi H, Roy C, Baron G, Lemann M, Puechal X, et al, and the RATIO (Research Axed on Tolerance of Biotherapies) Study Group. Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis 2007;66:1610-5.
24. Pai M, Joshi R, Dogra S, Mendiratta DK, Narang P, Kalantri S, et al. Serial testing of health care workers for tuberculosis using interferon-γ assay. Am J Respir Crit Care Med 2006;174:349-55.
25. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
26. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
27. Comstock GW, Edwards LB, Philip RN, Winn WA. A comparison in the United States of America of two tuberculins, PPD-S and RT 23. Bull World Health Organ 1964;31:161-70.
28. American Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000;161:1376-95.
29. Mori T, Sakatani M, Yamagishi F, Takashima T, Kawabe Y, Nagao K, et al. Specific detection of tuberculosis infection: an interferon-γ-based assay using new antigens. Am J Respir Crit Care Med 2004;170:59-64.
30. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 1949;25:659-62.
31. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46:2294-300.
32. Musellim B, Erturan S, Sonmez Duman E, Ongen G. Comparison of extra-pulmonary and pulmonary tuberculosis cases: factors influencing the site of reactivation. Int J Tuberc Lung Dis 2005;9:1220-3.
33. Gomez-Reino JJ, Carmona L, Descalzo MA, for the BIOBADASER Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007;57:756-61.
34. Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A, Cucho M, Alfaro J, Perich R, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005;64:1360-1.
35. Huebner RE, Schein MF, Bass JB Jr. The tuberculin skin test. Clin Infect Dis 1993;17:968-75.
36. Vigna-Perez M, Abud-Mendoza C, Portillo-Sallazar H, Alvarado-Sanchez B, Cuevad-Orta E, Moreno-Valdes R, et al. Immune effects of therapy with Adalimumab in patients with rheumatoid arthritis. Clin Exp Immunol 2005;141:372-80.
37. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006;10:1192-204.
38. Hatemi G, Melikoglu M, Fresko I, Masatlioglu S, Tascilar K, Yazici H. Infliximab does not suppress the tuberculin skin test (purified protein derivative). J Rheumatol 2007;34:474-80.
39. Menzies R, Vissandjee B, Rocher I, St Germain Y. The booster effect in two-step tuberculin testing among young adults in Montreal. Ann Intern Med 1994;120:190-8.
40. Lifson AR, Grant SM, Lorvick J, Pinto FD, He H, Thompson S, et al. Two-step tuberculin skin testing of injection drug users recruited from community-based settings. Int J Tuberc Lung Dis 1997;1:128-34.
41. Miret-Cuadras P, Pina-Gutierrez JM, Juncosa S. Tuberculin reactivity in Bacillus Calmette-Guérin vaccinated subjects. Tuber Lung Dis 1996;77:52-8.
42. Kraut A, Coodin M, Plessis R, McLean D. Predictors of positive tuberculin skin test (TST) results after 2-step TST among health care workers in Manitoba, Canada. Clin Infect Dis 2004;39:e113-8.
43. Joven BE, Almodovar R, Galindo M, Mateo I, Pablos JL. Does anti-tumor necrosis factor a treatment modify the tuberculin PPD response? [letter]. Ann Rheum Dis 2006;65:699.
44. Small PM, Fujiwara PI. Management of tuberculosis in the Unites States. N Engl J Med 2001;345:189-200.
45. Doherty TM, Demissie A, Olobo J, Wolday D, Britton S, Eguale T, et al. Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patient. J Clin Microbiol 2002;40:704-6.
46. Kobashi Y, Obase Y, Fukuda M, Yoshida K, Miyashita N, Oka M. Clinical revaluation of the QuantiFERON TB-2G test as a diagnostic method for differentiating active tuberculosis from nontuberculous mycobacteriosis. Clin Infect Dis 2006;43:1540-6.
47. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007;146:340-54.
48. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935-52.
49. Fietta A, Meloni F, Cascina A, Morosini M, Marena C, Troupioti P, et al. Comparison of a whole-blood interferon-γ assay and tuberculin skin testing in patients with active tuberculosis and individuals at high or low risk of Mycobacterium tuberculosis infection. Am J Infect Control 2003;31:347-53.
50. Kang Y, Lee HW, Yoon HI, Cho B, Han SK, Shim YS, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon γ assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005;293:2756-61.
51. Hotta K, Ogura T, Nishii K, Kodani T, Onishi M, Shimizu Y, et al. Whole blood interferon-γ assay for baseline tuberculosis screening among Japanese healthcare students. PloS ONE 2007;2:e803.
52. Ferrara G, Losi M, Meacci M, Meccugni B, Piro R, Roversi P, et al. Routine hospital use of a new commercial whole blood interferon-γ assay for the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 2005;172:631-5.
53. Hirsch CS, Toossi Z, Othieno C, Johnson JL, Schwander SK, Robertson S, et al. Depressed T-cell interferon-γ responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy. J Infect Dis 1999;180:2069-73.
54. Carrara S, Vincenti D, Petrosillo N, Amicosante M, Girardi E, Goletti D. Use of a T cell-based assay for monitoring efficacy of antiuberculosis therapy. Clin Infect Dis 2004;38:754-6.
55. Wilkinson KA, Kon OM, Newton SM, Meintjes G, Davidson RN, Pasvol G, et al. Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens. J Infect Dis 2006;193:354-9.